Trial · NCT05156905
Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer
NCT05156905, Phase 1, Terminated, University of California, San Diego
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer. Trials, record NCT05156905. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05156905
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer
- NCT number
- NCT05156905
- Status
- Terminated
- Phases
- Phase 1
- Enrollment
- 6 participants, actual
- Lead sponsor
- University of California, San Diego
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Cirmtuzumab
- First posted
- 2021-12-14
- Last updated
- 2024-10-09
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recommended phase 2 dose of docetaxel combined with cirmtuzumab | Patients will be followed from study entry to death or date last known alive, assessed up to 36 months | Defined by CTCAE version 5 grading |
| Secondary | Incidence of treatment-emergent adverse events | Patients will be followed from study entry to death or date last known alive, assessed up to 36 months | Defined by CTCAE version 5 grading |
| Secondary | Total alkaline phosphatase response | Patients will be followed from study entry to death or date last known alive, assessed up to 36 months | Defined as a reduction of ≥30% from the baseline value, confirmed ≥4 weeks later. |
| Secondary | Time to PSA progression | Patients will be followed from study entry to death or date last known alive, assessed up to 36 months | Defined by PCWG-3 criteria |
| Secondary | Time to increase in the total alkaline phosphatase level | Patients will be followed from study entry to death or date last known alive, assessed up to 36 months | Defined as an increase of ≥25% from baseline at ≥12 weeks, in patients with no decrease from baseline, or as an increase of ≥25% above the nadir, confirmed ≥3 weeks later, in patients with an initial decrease from baseline. |
| Secondary | Radiographic progression free survival | Patients will be followed from study entry to death or date last known alive, assessed up to 36 months | Defined by PCWG-3 criteria for bone metastases and RECIST version 1.1 for soft tissue |
| Secondary | Time to first subsequent anti-cancer therapy | Patients will be followed from study entry to death or date last known alive, assessed up to 36 months | Time from study discontinuation to initiation of subsequent systemic anti-cancer therapy or death |
| Secondary | Time to first symptomatic skeletal event | Patients will be followed from study entry to death or date last known alive, assessed up to 36 months | Time to first symptomatic pathologic fracture, radiation to the bone given symptomatic bone metastasis, surgery to the bone given symptomatic bone metastasis, or symptomatic spinal cord compression |
| Secondary | Overall survival | Patients will be followed from study entry to death or date last known alive, assessed up to 36 months | Time from enrollment to death or last follow up |
| Secondary | Composite clinical benefit | Patients will be followed from study entry to death or date last known alive, assessed up to 36 months | Composite endpoint of clinical benefit defined as any one of the following: PSA response by PCWG3 criteria, objective response rate by RECIST version 1.1, and stable disease \> 6 months by RECIST version 1.1. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05156905
GET https://conductscience.org/api/trials/v1/NCT05156905/registered